Finds skin and blood markers that predict treatment response in chronic skin inflammation
Collects skin and blood samples to predict treatment response in chronic inflammatory skin diseases.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- Paris, FranceSee the site
- Trial code
- Registry title
- Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
- Status
- Recruiting
- People taking part
- 830 people, planned
- Started
- 20 Oct 2025
- Expected to end
- 20 Oct 2045
- Type of study
- Observational, 2 groups
- Treatments tested
- Sampling
- Record updated
- 12 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe long-lasting inflammatory skin disease, or active leprosy. It also takes healthy adults having plastic surgery as controls.
- Age
- Over 18 years
- Sex
- All
- Disease stage
- Moderate to severe chronic inflammatory skin disease (IGA score 3 or 4), such as atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, morphea, neutrophilic dermatosis, cutaneous granulomatosis, cutaneous vasculitis or autoimmune bullous dermatosis. Or active leprosy, but not pure neurological leprosy. Healthy controls have no known inflammatory skin disease.
- Earlier treatment
- People cannot have taken an immunosuppressant (including corticosteroids) or an immunomodulator now or in the last 3 months.
Main reasons for not taking part
- Under guardianship or curatorship
- Pregnant or breastfeeding woman
- Not covered by a social security system
- Current or recent (last 3 months) immunosuppressant or immunomodulator treatment, including corticosteroids
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients:
- Age>18 years
- Informed consent signed by the patient
- Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis, cutaneaous vasculitis, autoimmune bullous dermatosis
- Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification [1], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction); Healthy controls :
- Age>18 years
- Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants
- Informed consent signed by the patient
- Absence of known cutaneous inflammatory disease
Who cannot take part
- Current systemic treatment with immunosupressant (including corticosteroid therapy) or an immunomodulator or received within the last 3 months
- Under guardianship or curatorship
- Pregnant or breastfeeding woman
- Lack of affiliation with a social security system
Where in France
- Hopital Saint LouisParis, FranceContact: Charles Cassius, MD phDTaking people
About the trial
What the trial wants to find out
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases.
Read full original descriptionShow less
The main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases.
The secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.
The 2 groups in the trial
- Patients
Affected by inflammatory skin disease
Treatment: Sampling
- Controls
Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants
Treatment: Sampling
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Identification Des Marqueurs Biologiques cutanés et Sanguins prédictifs de réponse Aux Traitements systémiques au Cours Des Maladies cutanées Inflammatoires Chroniques
- Plain-language title
- Finds skin and blood markers that predict treatment response in chronic skin inflammationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 June 2026